Form 4: BridgeBio Pharma Director Andrea Ellis Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Andrea Ellis exercised stock options and sold shares of BridgeBio Pharma, Inc. under a pre-arranged 10b5-1 trading plan.

Summary

• On April 14, 2025, Andrea Ellis, a director of BridgeBio Pharma, Inc. (BBIO), executed a transaction involving the company's common stock.
• Ellis exercised a stock option to acquire 10,000 shares at a price of $8.45 per share.
• Simultaneously, Ellis sold 10,000 shares at a price of $35 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 sales plan adopted on December 30, 2024.
• Following these transactions, Ellis directly owns 12,000 shares of common stock and 64,921 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, and 10% owners) trade in their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects. The use of a 10b5-1 plan indicates that the insider's trading activities were pre-planned and not based on any material non-public information at the time of the trade.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and Form 4 filings are a standard part of regulatory compliance.
• The use of a 10b5-1 plan is a common practice among corporate insiders to avoid accusations of illegal insider trading.
• Comparable companies in the biotechnology sector, such as Amgen (AMGN) and Gilead Sciences (GILD), also have frequent Form 4 filings related to insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a director.
• The impact is likely minimal as the transactions were executed under a pre-arranged 10b5-1 plan.

Key Dates

Keywords

Form 4, BridgeBio Pharma, BBIO, Andrea Ellis, Stock Option, Share Sale, 10b5-1 Plan, Director, Insider Trading